公开(公告)号：US20240392032A1

公开(公告)日：2024-11-28

申请号：US18617483

申请日：2024-03-26

Applicant: Genmab A/S

Inventor： David SATIJN ,  Esther C.W. Breij ,  Bart E.C.G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20230132049A1

公开(公告)日：2023-04-27

申请号：US17938523

申请日：2022-10-06

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Patrick Engelberts ,  Kristel Kemper ,  Esther C.W. Breij ,  Simone OOSTINDIE ,  Farshid ALEMDEHY

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/00

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.